rs6031552 — HNF4A HNF4A Regulatory Variant

HNF4A P2 Haplotype — A Regulatory Switch for Beta-Cell Identity

HNF4A¹¹ HNF4A
Hepatocyte Nuclear Factor 4 Alpha — a nuclear receptor transcription factor expressed in liver, intestine, kidney, and pancreatic beta cells is one of the master regulators of metabolic gene expression. It controls dozens of genes involved in glucose production, fatty acid oxidation, and cholesterol transport. HNF4A is unique in having two distinct promoters — P1, active in adult liver, and P2, active in pancreatic beta cells and the fetal liver — each driving a different isoform of the protein. rs6031552 sits in an intronic position within HNF4A that falls inside the haplotype block surrounding the P2 promoter, approximately 45 kb upstream of the HNF4A coding region. It tags the same risk signal as the better-studied P2 variants rs1884613 and rs2144908, meaning carriers of the A allele are likely carriers of the extended P2 risk haplotype.

The Mechanism

The P2 promoter drives the "fetal" isoform of HNF4A (HNF4A7–12), which is normally silenced in adult liver but remains persistently active in pancreatic beta cells. Common variants in the P2 region appear to subtly alter promoter activity, influencing how much of this isoform is produced. In the pancreas, dysregulation of HNF4A P2 isoform levels impairs glucose-stimulated insulin secretion — the fundamental mechanism of pancreatic beta-cell function. In the adult liver, the P2 isoform becomes aberrantly upregulated in type 2 diabetes²² aberrantly upregulated in type 2 diabetes
Chronically elevated P2 isoform in diabetic liver drives excess hepatic glucose production, compounding hyperglycemia. This happens through a glucagon-TET3-FOXA2 epigenetic axis: glucagon (elevated in diabetes) stimulates TET3 expression, which demethylates the P2 promoter and increases transcription. The result is excessive hepatic glucose production on top of impaired beta-cell insulin release — a double hit on glucose homeostasis.

Rare mutations in the P2 promoter itself cause MODY1³³ MODY1
Maturity-Onset Diabetes of the Young type 1 — a monogenic, autosomal dominant form of early-onset diabetes caused by HNF4A haploinsufficiency in beta cells. The common P2 haplotype variants captured by rs6031552 are not MODY mutations but operate through the same pathway at much smaller effect sizes, contributing to polygenic type 2 diabetes susceptibility.

The Evidence

The original P2 haplotype association with type 2 diabetes was reported in Finnish and Ashkenazi populations in 2004, linking four common P2 promoter variants⁴⁴ four common P2 promoter variants
rs4810424, rs2144908, rs1884613, rs1884614 — all in strong LD within the P2 haplotype block to diabetes in 5,256 UK subjects (OR 1.15, 95% CI 1.02–1.33, P=0.02). A 2007 meta-analysis by Grarup et al.⁵⁵ Grarup et al.
Studies in 3,523 Norwegians and meta-analysis in 11,571 subjects indicate HNF4A P2 region variants are associated with type 2 diabetes in Scandinavians. Diabetes, 2007 confirmed the association in Scandinavian populations with a pooled OR of 1.14 (95% CI 1.06–1.23, P=0.0004) across 4,000 cases and 7,571 controls. The P2 haplotype also associated with earlier age at type 2 diabetes diagnosis in Mexican-American families (P=0.003), where the risk allele frequency is ~53% — substantially higher than in Europeans (~21%) or East Asians (~19%).

A critical caveat: the risk conferred by the P2 haplotype is population-specific⁶⁶ population-specific
Gudmundsson et al. 2008 showed OR ~1.7 in Ashkenazi Jewish subjects versus OR 1.04 (NS) in UK populations, despite both groups having similar P2 haplotype frequencies. This implies that the causal variant within the haplotype block remains unidentified, and the P2 tag SNPs (including rs6031552) differ in their LD with the actual functional variant across populations. For rs6031552 specifically, it was genotyped as part of a 9-SNP HNF4A panel in 160 subjects by Saif-Ali et al. 2011⁷⁷ Saif-Ali et al. 2011
Saif-Ali et al. Nine HNF4A SNPs including rs6031552; the CCCGTC haplotype associated with higher insulin resistance (p=0.022) and lower HDL (p=0.001). Acta Biochim Pol, 2011, which found that the common P2 haplotype (CCCGTC) was associated with higher insulin resistance and lower HDL cholesterol in subjects without diabetes — suggesting pre-diabetic metabolic perturbation in haplotype carriers.

The evidence is classified as moderate: the P2 haplotype association is well-replicated across populations, but the effect per allele is modest (OR ~1.14–1.21), rs6031552's independent contribution is unclear beyond its role as a haplotype tag, and the causal variant has not been functionally resolved.

Practical Actions

The A allele at rs6031552 tags the P2 risk haplotype. The primary risk it confers is for type 2 diabetes and insulin resistance through impaired beta-cell insulin secretion. Individuals carrying one or two A alleles should focus on maintaining insulin sensitivity: reducing fasting glucose through dietary carbohydrate quality (low glycemic index foods reduce beta-cell demand), monitoring fasting glucose and HbA1c periodically, and considering whether they have additional risk factors (obesity, family history, sedentary lifestyle) that would compound the genetic signal. Since the P2 haplotype also associated with lower HDL cholesterol in the Saif-Ali haplotype study, lipid monitoring is also warranted. For AA homozygotes — carrying both copies of the risk haplotype — the combination of impaired insulin secretion and reduced HDL makes cardiovascular metabolic screening a priority.

Interactions

rs6031552 is in strong linkage disequilibrium with the better-studied P2 haplotype SNPs rs1884613, rs2144908, rs4810424, and rs1884614. These are all tags for the same underlying haplotype block. Having risk alleles at multiple P2 SNPs does not represent independent cumulative risk — they capture the same haplotype signal.

The P2 pathway intersects with variants in KCNJ11 (rs5219) and TCF7L2 (rs7903146), which affect beta-cell insulin secretion through different mechanisms (KATP channel and Wnt/incretin signaling, respectively). Carriers of the HNF4A P2 risk haplotype who also carry TCF7L2 or KCNJ11 risk alleles would have multiple beta-cell secretory deficits — a profile warranting earlier and more frequent glucose monitoring. A compound action is warranted for this combination if both SNPs are present in the database.